MA34097B1 - Utilisations d'inhibiteurs de dgat1 - Google Patents

Utilisations d'inhibiteurs de dgat1

Info

Publication number
MA34097B1
MA34097B1 MA35264A MA35264A MA34097B1 MA 34097 B1 MA34097 B1 MA 34097B1 MA 35264 A MA35264 A MA 35264A MA 35264 A MA35264 A MA 35264A MA 34097 B1 MA34097 B1 MA 34097B1
Authority
MA
Morocco
Prior art keywords
prevention
dgat1
inhibitors
syndrome
disease
Prior art date
Application number
MA35264A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Charles Meyers
Michael H Serrano-Wu
Tom Thuren
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44170024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34097(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34097B1 publication Critical patent/MA34097B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA35264A 2010-03-30 2011-03-29 Utilisations d'inhibiteurs de dgat1 MA34097B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31881410P 2010-03-30 2010-03-30
PCT/US2011/030234 WO2011123401A1 (en) 2010-03-30 2011-03-29 Uses of dgat1 inhibitors

Publications (1)

Publication Number Publication Date
MA34097B1 true MA34097B1 (fr) 2013-03-05

Family

ID=44170024

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35264A MA34097B1 (fr) 2010-03-30 2011-03-29 Utilisations d'inhibiteurs de dgat1

Country Status (20)

Country Link
US (1) US9061012B2 (enExample)
EP (1) EP2552441B1 (enExample)
JP (2) JP2013523746A (enExample)
KR (1) KR20130073884A (enExample)
CN (1) CN102834099B (enExample)
AU (1) AU2011235301B2 (enExample)
BR (1) BR112012024618A2 (enExample)
CA (1) CA2792269A1 (enExample)
CL (1) CL2012002716A1 (enExample)
ES (1) ES2586127T3 (enExample)
MA (1) MA34097B1 (enExample)
MX (1) MX2012011333A (enExample)
NZ (1) NZ602125A (enExample)
PH (1) PH12012501859A1 (enExample)
RU (1) RU2012145950A (enExample)
SG (1) SG183529A1 (enExample)
TN (1) TN2012000458A1 (enExample)
TW (1) TW201136916A (enExample)
WO (1) WO2011123401A1 (enExample)
ZA (1) ZA201206456B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
JP2015520136A (ja) * 2012-04-25 2015-07-16 コリア リサーチ インスティチュート オブ ケミカル テクノロジーＫｏｒｅａ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｃｈｅｍｉｃａｌｔｅｃｈｎｏｌｏｇｙ 新規なベータアラニン誘導体、薬学的に許容される塩、及びそれを有効成分として含有する医薬組成物
WO2013169648A1 (en) 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
AU2014216137B2 (en) * 2013-02-14 2018-05-10 Ionis Pharmaceuticals, Inc. Modulation of Apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations
WO2015143178A1 (en) 2014-03-20 2015-09-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
HK1231380A1 (zh) * 2014-06-26 2017-12-22 Cymabay Therapeutics, Inc. 严重高甘油三酯血症的治疗
US20180125816A1 (en) 2015-05-11 2018-05-10 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
MY205335A (en) * 2018-03-16 2024-10-16 Anji Pharmaceuticals Inc Compositions and methods for treating severe constipation
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
TWI809427B (zh) 2018-07-13 2023-07-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
EP3870566A1 (en) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
EP3886871A4 (en) * 2018-11-30 2022-08-31 HDL Therapeutics, Inc. METHODS OF TREATMENT OF LIPID-RELATED DISEASES, INCLUDING XANTHOMA, CAROTID TENOSIS AND CEREBRAL ATHEROSCLEROSIS
JP2021001143A (ja) * 2019-06-21 2021-01-07 小林製薬株式会社 乳び血漿改善剤

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045439A1 (en) 1996-05-30 1997-12-04 The Trustees Of Columbia University In The City Of New York Dna encoding acylcoenzyme a: cholesterol acyltransferase and uses thereof
WO1999067268A1 (en) 1998-06-24 1999-12-29 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US6344548B1 (en) 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US20030154504A1 (en) 1998-06-24 2003-08-14 Farese Robert V. Methods and compositions for modulating carbohydrate metabolism
US20030167483A1 (en) 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
US6444427B1 (en) 2000-07-11 2002-09-03 The Regents Of The University Of California Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
WO2004047755A2 (en) 2002-11-22 2004-06-10 Japan Tobacco Inc. Fused bicyclic nitrogen-containing heterocycles
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
DE10331202A1 (de) * 2003-07-10 2005-03-31 S.K. Enterprise Gmbh Verwendung von Molkenpermeat zur Behandlung des Metabolischen Syndroms
EP1653969A4 (en) 2003-08-07 2006-12-20 Japan Tobacco Inc PYRROLO 1,2-B PYRIDAZINE DERIVATIVES
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
KR20060114376A (ko) 2004-01-30 2006-11-06 니뽄 다바코 산교 가부시키가이샤 식욕 감퇴 화합물
JP2006045209A (ja) 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
EP1764360A4 (en) 2004-07-02 2010-08-11 Sankyo Co UREA DERIVATIVE
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
CN101087769A (zh) 2004-10-15 2007-12-12 拜尔药品公司 用于治疗肥胖的联苯－4－基－羰基氨基酸衍生物的制备及用途
JP2006166742A (ja) * 2004-12-14 2006-06-29 Japan Health Science Foundation 高トリグリセリド血症の成因となる２種類のリポタンパクリパーゼ（ｌｐｌ）遺伝子変異及びそれを利用した高トリグリセリド血症を診断するためのｌｐｌ変異検出キット
CA2588162A1 (en) 2004-12-14 2006-06-22 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
EP2402317B1 (en) 2006-03-31 2013-07-03 Novartis AG DGAT inhibitor
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
BRPI0913986A2 (pt) * 2008-03-26 2015-10-20 Daiichi Sankyo Co Ltd composto, composição farmacêutica, e, uso de um composto

Also Published As

Publication number Publication date
KR20130073884A (ko) 2013-07-03
ZA201206456B (en) 2013-05-29
CN102834099B (zh) 2015-05-27
JP6251321B2 (ja) 2017-12-20
TN2012000458A1 (en) 2014-01-30
CL2012002716A1 (es) 2013-01-25
NZ602125A (en) 2014-01-31
US20130023495A1 (en) 2013-01-24
CA2792269A1 (en) 2011-10-06
SG183529A1 (en) 2012-10-30
EP2552441A1 (en) 2013-02-06
ES2586127T3 (es) 2016-10-11
RU2012145950A (ru) 2014-05-10
JP2016216466A (ja) 2016-12-22
PH12012501859A1 (en) 2013-01-07
MX2012011333A (es) 2012-11-16
EP2552441B1 (en) 2016-05-04
AU2011235301B2 (en) 2013-07-18
CN102834099A (zh) 2012-12-19
US9061012B2 (en) 2015-06-23
BR112012024618A2 (pt) 2019-09-24
WO2011123401A1 (en) 2011-10-06
TW201136916A (en) 2011-11-01
JP2013523746A (ja) 2013-06-17
AU2011235301A1 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
MA34097B1 (fr) Utilisations d'inhibiteurs de dgat1
MA37850A1 (fr) Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
PH12022550469A1 (en) Kras g12d inhibitors
JOP20210193A1 (ar) مثبطات pcsk9 وطرق استخدامها
EA201491008A1 (ru) Комбинация антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита
EA201592304A1 (ru) Способы лечения аутосомно-доминантой гиперхолестеринемии, ассоциированной с мутацией приобретения функции гена pcsk9
EA200971053A1 (ru) Способы лечения кожных язв
JP2010532765A5 (enExample)
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
JP2017515893A5 (enExample)
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MA37829A1 (fr) Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha
MX2009008051A (es) Regimen posologico para inhibidores de comt.
EA201590726A1 (ru) Лахинимод для уменьшения таламического поражения при рассеянном склерозе
WO2020186132A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
TN2016000040A1 (fr) Inhibiteurs de porc2 et procedes pour leur utilisation
EP2572721A4 (en) Pharmaceutical composition including an hif-2 inhibitor as an active ingredient for preventing or treating arthritis
UA111599C2 (uk) Композиція каспофунгіну
WO2014194226A3 (en) Methods of treatment and compositions with xanthine oxidase inhibitors
ATE507214T1 (de) Neuartige serotonin-wiederaufnahmehemmer als arzneimittel mit peripheriesystem-beschränkter aktivität
ATE401913T1 (de) Behandlung oder prävention von unplanmässigen blutungen bei frauen unter progestogenhaltiger medikation
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EP2716300A4 (en) APPLICATION TO PRDX2 AND / OR PRDX6 IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DAMAGE, AGING OR DISEASE AS A RESULT OF INCREASING THE REACTIVE OXYGEN SPECIES
WO2019017677A3 (ko) 시트랄을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소증 억제효과를 갖는 조성물
WO2019004788A3 (ko) 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물